Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Guided from the start by data from in vivo models, Gabather is discovering new ways to manipulate the neurotransmitter γ-aminobutyric acid (GABA) to more effectively treat patients with psychiatric and neurological disorders, without producing sedative side effects.
By reprogramming the tumor microenvironment Kineta is developing an anti-VISTA immuno-oncology therapy for the treatment of a variety of cancers, including gastric, ovarian, lung and pancreatic cancers.
Cyclica’s drug discovery platform accelerates preclinical drug development by predicting the polypharmacological profile and medicinal properties of drug candidates.
Biotech company PsiVac is developing Ixovex-1, the first patented virus with a single base pair mutation able to replicate rapidly, opening potential new treatment options for solid tumors and beyond.
Using its MicroRx platform, 4D pharma is pioneering the development of an emerging class of therapeutics known as live biotherapeutic products to treat a range of indications from cancer and respiratory disease to neurodegeneration.
The market for drugs to treat central nervous system disorders is set for growth, supported by the continued strength of therapies for multiple sclerosis.
Sorrento Therapeutics, Inc. is developing a pipeline of fully human immunotherapies selected from its proprietary G-MAB library. Backed by a platform covering discovery, advanced clinical development, manufacturing and a proven track record of commercialization, it seeks to deliver life-changing therapies.
Privately held Creatv MicroTech has developed LifeTracDx tests to detect cancer at the earliest stages, and for providing diagnoses to guide cancer treatments, thereby saving and improving lives.
RubrYc Therapeutics has established an antibody discovery engine for the development of epitope-targeted biotherapeutics. Through machine learning, the platform helps reveal natural subdominant and alternative epitopes to target for optimized bio-superior design and as access points to traditionally ‘undruggable’ proteins.
Biotech company APO-T is developing bispecific T cell engagers (BiTEs) that facilitate the attraction of immune effector cells exclusively to cancer sites by targeting cancer cell antigens known as melanoma-associated antigen A (MAGE-A) proteins.
IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg-derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever.
Carisma Therapeutics is developing unique CAR macrophage therapies to treat solid tumors. The company’s lead CAR-M program, CT-0508, is ready to enter phase 1 testing.
Combining the precision of antibody targeting with α-amanitin, a novel payload, Heidelberg Pharma has developed a powerful therapeutic platform, with the potential to treat a broad range of cancers.
3T Biosciences has developed an immune response-guided approach for identifying pharmacologically active T cell receptors and their targets in solid tumors. With a pipeline of therapeutics targeting novel tumor antigens, 3T is seeking partners to advance these programs.
ExosomeDx harnesses biological information from exosomes for biomarker discovery and diagnostic development. The company’s pipeline of products includes the ExoDx Prostate test, the first exosome-based liquid biopsy on the market, and various discovery platforms to help solve biopharma’s biomarker-related needs.
Precision NanoSystems is developing nanoparticle-delivered drugs through its NanoAssemblr technology, helping companies solve drug delivery challenges in cancer, rare diseases and infectious diseases.
Rakuten Medical, a clinical-stage privately funded biotechnology company, is developing first-in-class targeted cancer therapies based on Illuminox, a new platform with the potential to treat many types of solid tumor, one of the leading causes of death globally.
Employing its deep understanding of G-protein coupled receptors (GPCRs) the Beacon Discovery team has delivered more than 20 compounds into clinical development over the past two decades, and is now working with partners to unlock the therapeutic value of challenging receptors in this class.
With expertise, capabilities, and capacity in abundance, the Cellex Group is an experienced facility worldwide for allogeneic bone marrow, peripheral blood stem cell and other cellular blood components, and is now growing to become a complete service provider for cellular immunotherapy products.
